This brings up an interesting scenario.

Let’s say the primary endpoint does not reach statistical significance.

However, the Crestor subgroup and one or both of the CKD and Dementia ones do.

What will the market do?

I would suggest that we could see some initial selling followed by some powerful buying.

Any large pharma would want to partner on a CKD or Dementia trial. I believe this would be true even if the Crestor subgroup was negative.

So, don’t be so quick to jettison your shares if the primary endpoint is negative!

bfw